黄豆苷元干预老年冠心病患者血清炎性因子的临床观察

目的 观察黄豆苷元（Daidzein，DZ）对冠心痛患者血清炎性因子的影响。方法 40例老年冠心病患者随机分为对照组和用药组各20例。对照组给予常规用药治疗，用药组在常规治疗的基础上加用黄豆苷元片治疗6周，分别在治疗前后测量基础心率（RHR）、血压（BP）、空腹静脉血糖（FPG）、血脂以及炎性因子（hsCRP、IL-6和TNF-α）。结果 对照组患者治疗后，除了RHR、BP和hsCRP较治疗前有改变外（P〈0．05或P〈0．01），其余指标没有变化（P〉0．05）。用药组治疗后，RHR、BP、FPG、血脂和各项炎性因子较治疗前和对照组治疗后均有不同程度的下降（P〈0．05或P〈0．01）。结论 黄豆苷元能够有效地抑制老年冠心病患者血清炎性因子的水平，异黄酮类药物对冠状动脉粥样硬化具有抗炎作用。

Clinical Observation of Daidzein Intervention on Serum Inflammatory Factors in Senile Patients with Coronary Heart Disease

OBJECTIVE: To observe the effect of daidzein on serum inflammatory factors of senile patients with coronary heart disease (CHD). METHODS: Forty senile patients with CHD were randomly assigned into the control group and the daidzein group, 20 in each group. Patients in both groups were treated with conventional medicine, while those in the daidzein group were given daidzein Tablets additionally for 6 weeks. The levels of resting heart rate (RHR), blood pressure (BP), fasting plasma glucose (FPG), blood lipids and inflammatory factors, including hsCRP, IL-6 and TNF-alpha, were measured before and after treatment. RESULTS: In the control group, the levels of RHR, BP and hsCRP changed after conventional medicinal treatment (P < 0.05 or P < 0.01) but other parameters unchanged (P > 0.05). While in the daidzein group, all the parameters measured were decreased in different degrees after 6 weeks treatment (P < 0.05 or P < 0.01), and also showed significant difference as compared with those in the control group respectively (P < 0.05 or P < 0.01). CONCLUSION: Daidzein can effectively decrease the levels serum inflammatory factors in senile patients with CHD, the fact proved that isoflavone has anti-inflammatory effect in patients with coronary atherosclerosis.